Angioimmunoblastic T-Cell Lymphoma Market Report Insights What is Angioimmunoblastic T-Cell Lymphoma? Angioimmunoblastic T-Cell Lymphoma (AITL) is a rare form of non-Hodgkin lymphoma, which is a group of related malignancies (cancers) that affect the lymphatic system (lymphomas). How many people are affected by Angioimmunoblastic T-Cell Lymphoma?
As per DelveInsight estimates, the incident cases of Peripheral T-Cell Lymphoma (PTCL) in the 7MM was 16,298 cases in 2017. These cases is expected to increase at significant rate during the forecast period. Estimates suggested that the United States accounts for 37.5% of all incident cases of PTCL among the 7MM. In 2017, there were a total of 6,110 incident cases of PTCL in the US, which are anticipated to increase during the forecast period (2020-2030). The United States had the highest percentage of incidence of AITL in 2017.
How will Angioimmunoblastic T-Cell Lymphoma Market change in upcoming years?
According to DelveInsight, Angioimmunoblastic T-Cell Lymphoma market in 7MM is expected to change in the study period 2017-2030. AITL is one of the most common types of PTCL, typically present with advanced disease, systemic symptoms, and immune deregulation. Treatment can be challenging owing to frequent relapses after initial and subsequent therapy. The choice of front-line treatment depends on the goal of therapy. For most AITL patients, the initial goal of treatment is curative; therefore, an aggressive approach with combination chemotherapy followed often by consolidation with autologous stem-cell transplant (ASCT)